Cytogen: Prostascint may help predict prostate cancer recurrence

By Elaine Rigoli

Tampa, Fla., May 24 - Cytogen Corp. released seven-year outcomes data relating to Prostascint (capromab pendetide), a commercial monoclonal antibody-based agent that targets prostate-specific membrane antigen to image the extent and spread of prostate cancer.

For the entire group, which consists of 217 patients with local disease and 22 patients with extraprostatic disease, biochemical disease-free survival at seven years for patients in whom the Prostascint scan showed disease confined to the prostate as opposed to those who had uptake outside the peri-prostatic region was 91% versus 66%, 87% versus 46% by the PSA <1.0 criteria, and 86% versus 44% by the PSA <0.5 criteria.

For the hormonal naive sub-population (171 localized, 18 extraprostatic), the seven-year biochemical disease-free survival was 92% versus 64%, 88% versus 31% (p<0.0001) and 87% versus 30% (p<0.0001) with the same criteria.

About 85% of all prostate cancer cases diagnosed are clinically localized and treated with radical prostatectomy or radiation therapy, officials said.

Cytogen said managing these patients is complicated because it is difficult to accurately predict which patients are at high or low risk for developing prostate cancer recurrence following therapy.

The study evaluated the use of fusion imaging with Prostascint to assess disease in 239 newly diagnosed prostate cancer patients prior to undergoing brachytherapy with either iodine-125 or palladium-103 radioactive seed implants.

Fusion imaging with Prostascint, or hybrid imaging, is an in-vivo diagnostic technique that combines anatomic images with functional images.

Cytogen is a biopharmaceutical company based in Princeton, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.